Polymorphisms in TBX21 and STAT4 increase the risk of systemic sclerosis: Evidence of possible gene-gene interaction and alterations in Th1/Th2 cytokines

Arthritis and Rheumatism

Volumn 60, Issue 12, 2009, Pages 3794-3806

  Gourh, Pravitt ^a   Agarwal, Sandeep K ^a   Divecha, Dipal ^a   Assassi, Shervin ^a   Paz, Gene ^a   Arora Singh, Rajpreet K ^a   Reveille, John D ^a   Shete, Sanjay ^b   Mayes, Maureen D ^a   Arnett, Frank C ^a   Tan, Filemon K ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; INTERFERON; INTERLEUKIN 13; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; STAT4 PROTEIN; TRANSCRIPTION FACTOR T BET; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; AUTOIMMUNE DISEASE; CONTROLLED STUDY; DISEASE PREDISPOSITION; FEMALE; GENE EXPRESSION; GENE INTERACTION; GENOTYPE; HUMAN; HUMAN CELL; IMMUNE DYSREGULATION; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SKIN FIBROSIS; SYSTEMIC SCLEROSIS; TH1 CELL; TH2 CELL;

COHORT STUDIES; CYTOKINES; EPISTASIS, GENETIC; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS; SCLERODERMA, SYSTEMIC; STAT4 TRANSCRIPTION FACTOR; T-BOX DOMAIN PROTEINS; TH1 CELLS; TH2 CELLS;

EID: 73249149749     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.24958     Document Type: Article

References (52)

1. Bernatsky S, Joseph L, Pineau CA, Belisle P, Hudson M, Clarke AE. Scleroderma prevalence: demographic variations in a population-based sample. Arthritis Rheum 2009;61:400-4.
2. Gourh P, Tan FK, Assassi S, Ahn CW, McNearney TA, Fischbach M, et al. Association of the PTPN22 R620W polymorphism with anti-topoisomerase I- and anticentromere antibody-positive systemic sclerosis. Arthritis Rheum 2006;54:3945-53.
3. Alkassab F, Gourh P, Tan FK, McNearney T, Fischbach M, Ahn C, et al. An allograft inflammatory factor 1 (AIF1) single nucleotide polymorphism (SNP) is associated with anticentromere antibody positive systemic sclerosis. Rheumatology (Oxford) 2007;46: 1248-51.
4. Agarwal SK, Tan FK, Arnett FC. Genetics and genomic studies in scleroderma (systemic sclerosis). Rheum Dis Clin North Am 2008;34:17-40.
5. Wu SP, Leng L, Feng Z, Liu N, Zhao H, McDonald C, et al. Macrophage migration inhibitory factor promoter polymorphisms and the clinical expression of scleroderma. Arthritis Rheum 2006;54:3661-9.
6. Tan FK, Stivers DN, Arnett FC, Chakraborty R, Howard R, Reveille JD. HLA haplotypes and microsatellite polymorphisms in and around the major histocompatibility complex region in a Native American population with a high prevalence of scleroderma (systemic sclerosis). Tissue Antigens 1999;53:74-80.
7. Tan FK, Stivers DN, Foster MW, Chakraborty R, Howard RF, Milewicz DM, et al. Association of microsatellite markers near the fibrillin 1 gene on human chromosome 15q with scleroderma in a Native American population. Arthritis Rheum 1998;41:1729-37.
8. Tan FK, Wang N, Kuwana M, Chakraborty R, Bona CA, Milewicz DM, et al. Association of fibrillin 1 single-nucleotide polymorphism haplotypes with systemic sclerosis in Choctaw and Japanese populations. Arthritis Rheum 2001;44:893-901.
9. McHugh NJ, Whyte J, Artlett C, Briggs DC, Stephens CO, Olsen NJ, et al. Anti-centromere antibodies (ACA) in systemic sclerosis patients and their relatives: a serological and HLA study. Clin Exp Immunol 1994;96:267-74.
10. Arnett FC, Reveille JD, Goldstein R, Pollard KM, Leaird K, Smith EA, et al. Autoantibodies to fibrillarin in systemic sclerosis (scleroderma): an immunogenetic, serologic, and clinical analysis. Arthritis Rheum 1996;39:1151-60.
11. Douvas AS, Achten M, Tan EM. Identification of a nuclear protein (Scl-70) as a unique target of human antinuclear antibodies in scleroderma. J Biol Chem 1979;254:10514-22.
12. Tan EM, Rodnan GP, Garcia I, Moroi Y, Fritzler MJ, Peebles C. Diversity of antinuclear antibodies in progressive systemic sclerosis: anti-centromere antibody and its relationship to CREST syndrome. Arthritis Rheum 1980;23:617-25.
13. Arnett FC. HLA and autoimmunity in scleroderma (systemic sclerosis). Int Rev Immunol 1995;12:107-28.
14. Kalogerou A, Gelou E, Mountantonakis S, Settas L, Zafiriou E, Sakkas L. Early T cell activation in the skin from patients with systemic sclerosis. Ann Rheum Dis 2005;64:1233-5.
15. Molteni M, Della BS, Mascagni B, Bazzi S, Zulian C, Compasso S, et al. Increased interferon-γ (IFN-γ) levels produced in vitro by alloactivated T lymphocytes in systemic sclerosis and Raynaud's phenomenon. Clin Exp Immunol 1999;116:164-8.
16. Needleman BW, Wigley FM, Stair RW. Interleukin-1, interleukin-2, interleukin-4, interleukin-6, tumor necrosis factor α, and interferon-γ levels in sera from patients with scleroderma. Arthritis Rheum 1992;35:67-72.
17. Kahaleh MB, Leroy EC. Interleukin-2 in scleroderma: correlation of serum level with extent of skin involvement and disease duration. Ann Intern Med 1989;110:446-50.
18. Mavalia C, Scaletti C, Romagnani P, Carossino AM, Pignone A, Emmi L, et al. Type 2 helper T-cell predominance and high CD30 expression in systemic sclerosis. Am J Pathol 1997;151:1751-8.
19. Giacomelli R, Cipriani P, Lattanzio R, Di Franco M, Locanto M, Parzanese I, et al. Circulating levels of soluble CD30 are increased in patients with systemic sclerosis (SSc) and correlate with serological and clinical features of the disease. Clin Exp Immunol 1997;108:42-6.
20. Usui T, Preiss JC, Kanno Y, Yao ZJ, Bream JH, O'Shea JJ, et al. T-bet regulates Th1 responses through essential effects on GATA-3 function rather than on IFNG gene acetylation and transcription. J Exp Med 2006;203:755-66.
21. Szabo SJ, Kim ST, Costa GL, Zhang X, Fathman CG, Glimcher LH. A novel transcription factor, T-bet, directs Th1 lineage commitment. Cell 2000;100:655-69.
22. Chae SC, Shim SC, Chung HT. Association of TBX21 polymorphisms in a Korean population with rheumatoid arthritis. Exp Mol Med 2009;41:33-41.
23. Finotto S, Hausding M, Doganci A, Maxeiner JH, Lehr HA, Luft C, et al. Asthmatic changes in mice lacking T-bet are mediated by IL-13. Int Immunol 2005;17:993-1007.
24. Finotto S, Neurath MF, Glickman JN, Qin S, Lehr HA, Green FH, et al. Development of spontaneous airway changes consistent with human asthma in mice lacking T-bet. Science 2002;295:336-8.
25. Chung HT, Kim LH, Park BL, Lee JH, Park HS, Choi BW, et al. Association analysis of novel TBX21 variants with asthma phenotypes. Hum Mutat 2003;22:257.
26. Ylikoski E, Kinos R, Sirkkanen N, Pykalainen M, Savolainen J, Laitinen LA, et al. Association study of 15 novel single-nucleotide polymorphisms of the T-bet locus among Finnish asthma families. Clin Exp Allergy 2004;34:1049-55.
27. Sasaki Y, Ihara K, Matsuura N, Kohno H, Nagafuchi S, Kuromaru R, et al. Identification of a novel type 1 diabetes susceptibility gene, T-bet. Hum Genet 2004;115:177-84.
28. Aliprantis AO, Wang J, Fathman JW, Lemaire R, Dorfman DM, Lafyatis R, et al. Transcription factor T-bet regulates skin sclerosis through its function in innate immunity and via IL-13. Proc Natl Acad Sci U S A 2007;104:2827-30.
29. Lakos G, Melichian D, Wu M, Varga J. Increased bleomycininduced skin fibrosis in mice lacking the Th1-specific transcription factor T-bet. Pathobiology 2006;73:224-37.
30. Tan FK, Zhou X, Mayes MD, Gourh P, Guo X, Marcum C, et al. Signatures of differentially regulated interferon gene expression and vasculotrophism in the peripheral blood cells of systemic sclerosis patients. Rheumatology (Oxford) 2006;45:694-702.
31. Rueda B, Broen J, Simeon C, Hesselstrand R, Diaz B, Sanchez H, et al. The STAT4 gene influences the genetic predisposition to systemic sclerosis phenotype. Hum Mol Genet 2009;18:2071-7.
32. Remmers EF, Plenge RM, Lee AT, Graham RR, Hom G, Behrens TW, et al. STAT4 and the risk of rheumatoid arthritis and systemic lupus erythematosus. N Engl J Med 2007;357:977-86.
33. Pykalainen M, Kinos R, Valkonen S, Rydman P, Kilpelainen M, Laitinen LA, et al. Association analysis of common variants of STAT6, GATA3, and STAT4 to asthma and high serum IgE phenotypes. J Allergy Clin Immunol 2005;115:80-7.
34. Zervou MI, Mamoulakis D, Panierakis C, Boumpas DT, Goulielmos GN. STAT4: a risk factor for type 1 diabetes? Hum Immunol 2008;69:647-50.
35. Korman BD, Alba MI, Le JM, Alevizos I, Smith JA, Nikolov NP, et al. Variant form of STAT4 is associated with primary Sjögren's syndrome. Genes Immun 2008;9:267-70.
36. Mayes MD. The establishment and utility of a population-based registry to understand the epidemiology of systemic sclerosis. Curr Rheumatol Rep 2000;2:512-6.
37. Reveille JD, Fischbach M, McNearney T, Friedman AW, Aguilar MB, Lisse J, et al. Systemic sclerosis in 3 US ethnic groups: a comparison of clinical, sociodemographic, serologic, and immunogenetic determinants. Semin Arthritis Rheum 2001;30:332-46.
38. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980;23:581-90.
39. LeRoy EC, Medsger TA, Jr. Criteria for the classification of early systemic sclerosis. J Rheumatol 2001;28:1573-6.
40. Hom G, Graham RR, Modrek B, Taylor KE, Ortmann W, Garnier S, et al. Association of systemic lupus erythematosus with C8orf13-BLK and ITGAM-ITGAX. N Engl J Med 2008;358:900-9.
41. Mitchell MK, Gregersen PK, Johnson S, Parsons R, Vlahov D. The New York Cancer Project: rationale, organization, design, and baseline characteristics. J Urban Health 2004;81:301-10.
42. Yeager M, Orr N, Hayes RB, Jacobs KB, Kraft P, Wacholder S, et al. Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Nat Genet 2007;39:645-9.
43. Fritzler MJ, Kinsella TD. The CREST syndrome: a distinct serologic entity with anticentromere antibodies. Am J Med 1980; 69:520-6.
44. The International HapMap Project. Nature 2003;426:789-96.
45. Chowdhury F, Williams A, Johnson P. Validation and comparison of two multiplex technologies, Luminex and Mesoscale Discovery, for human cytokine profiling. J Immunol Methods 2009;340: 55-64.
46. Zhang H, Bonney G. Use of classification trees for association studies. Genet Epidemiol 2000;19:323-32.
47. Wu X, Gu J, Grossman HB, Amos CI, Etzel C, Huang M, et al. Bladder cancer predisposition: a multigenic approach to DNArepair and cell-cycle-control genes. Am J Hum Genet 2006;78: 464-79.
48. Arnett FC, Howard RF, Tan F, Moulds JM, Bias WB, Durban E, et al. Increased prevalence of systemic sclerosis in a Native American tribe in Oklahoma: association with an Amerindian HLA haplotype. Arthritis Rheum 1996;39:1362-70.
49. Lakos G, Melichian D, Wu M, Varga J. Increased bleomycininduced skin fibrosis in mice lacking the Th1-specific transcription factor T-bet. Pathobiology 2006;73:224-37.
50. Tantisira KG, Hwang ES, Raby BA, Silverman ES, Lake SL, Richter BG, et al. TBX21: a functional variant predicts improvement in asthma with the use of inhaled corticosteroids. Proc Natl Acad Sci U S A 2004;101:18099-104.
51. Ko FW, Lun SW, Wong CK, Szeto CC, Lam CW, Leung TF, et al. Decreased T-bet expression and changes in chemokine levels in adults with asthma. Clin Exp Immunol 2007;147:526-32.
52. Park JW, Min HJ, Sohn JH, Kim JY, Hong JH, Sigrist KS, et al. Restoration of T-box-containing protein expressed in T cells protects against allergen-induced asthma. J Allergy Clin Immunol 2009;123:479-85.